Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 193(2018) vom: 25. Aug., Seite 24-32
1. Verfasser: Lord, James D (VerfasserIn)
Weitere Verfasser: Long, S Alice, Shows, Donna M, Thorpe, Jerill, Schwedhelm, Katherine, Chen, Janice, Kita, Mariko, Buckner, Jane H
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Crohn's disease FOXP3 Helios IL-2, IL-6, IL-7, IL-21 Integrin Stat Th1 mehr... Th2 Treg Vedolizumab cT(FH) Antibodies, Monoclonal, Humanized CXCR5 protein, human Cytokines FOXP3 protein, human Forkhead Transcription Factors Gastrointestinal Agents IKZF2 protein, human Inflammation Mediators Integrins Receptors, CXCR5 integrin alpha4beta7 Ikaros Transcription Factor 148971-36-2 vedolizumab 9RV78Q2002
LEADER 01000naa a22002652 4500
001 NLM28488359X
003 DE-627
005 20231225044140.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2018.05.006  |2 doi 
028 5 2 |a pubmed24n0949.xml 
035 |a (DE-627)NLM28488359X 
035 |a (NLM)29842945 
035 |a (PII)S1521-6616(18)30065-2 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Lord, James D  |e verfasserin  |4 aut 
245 1 0 |a Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 27.08.2019 
500 |a Date Revised 27.08.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved. 
520 |a Integrin alpha4/beta7 on circulating lymphocytes identifies them as gut-tropic, and can be targeted by the humanized antibody vedolizumab to treat inflammatory bowel disease (IBD). We found lymphocytes expressing alpha4/beta7 were significantly more responsive to the pro-inflammatory cytokines IL-6, IL-7, and IL-21, and less responsive to the regulatory T cell (Treg)-supporting cytokine IL-2. Alpha4/beta7 was expressed by a smaller percent of FOXP3 + Helios+ thymically-derived Tregs (tTregs) than FOXP3 + Helios- peripherally-derived Tregs (pTregs) or FOXP3- effector T cells. Integrin alpha4/beta7+ CD4 T cells were also rare among cells expressing the Th2 marker CRTh2, but enriched in cells bearing the circulating T follicular helper cell marker CXCR5. Thus the effect of this anti-integrin therapy on the mucosal immune system may be more qualitative than quantitative, and selectively replace pro-inflammatory effector cells with Tregs and Th2 cells to facilitate immune tolerance in the mucosa without globally depleting lymphocytes from the intestinal mucosa 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Crohn's disease 
650 4 |a FOXP3 
650 4 |a Helios 
650 4 |a IL-2, IL-6, IL-7, IL-21 
650 4 |a Integrin 
650 4 |a Stat 
650 4 |a Th1 
650 4 |a Th2 
650 4 |a Treg 
650 4 |a Vedolizumab 
650 4 |a cT(FH) 
650 7 |a Antibodies, Monoclonal, Humanized  |2 NLM 
650 7 |a CXCR5 protein, human  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a FOXP3 protein, human  |2 NLM 
650 7 |a Forkhead Transcription Factors  |2 NLM 
650 7 |a Gastrointestinal Agents  |2 NLM 
650 7 |a IKZF2 protein, human  |2 NLM 
650 7 |a Inflammation Mediators  |2 NLM 
650 7 |a Integrins  |2 NLM 
650 7 |a Receptors, CXCR5  |2 NLM 
650 7 |a integrin alpha4beta7  |2 NLM 
650 7 |a Ikaros Transcription Factor  |2 NLM 
650 7 |a 148971-36-2  |2 NLM 
650 7 |a vedolizumab  |2 NLM 
650 7 |a 9RV78Q2002  |2 NLM 
700 1 |a Long, S Alice  |e verfasserin  |4 aut 
700 1 |a Shows, Donna M  |e verfasserin  |4 aut 
700 1 |a Thorpe, Jerill  |e verfasserin  |4 aut 
700 1 |a Schwedhelm, Katherine  |e verfasserin  |4 aut 
700 1 |a Chen, Janice  |e verfasserin  |4 aut 
700 1 |a Kita, Mariko  |e verfasserin  |4 aut 
700 1 |a Buckner, Jane H  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 193(2018) vom: 25. Aug., Seite 24-32  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:193  |g year:2018  |g day:25  |g month:08  |g pages:24-32 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2018.05.006  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 193  |j 2018  |b 25  |c 08  |h 24-32